Prevail Therapeutics
430 E. 29th street
suite 940
New York
NY
10016
United States
Website: http://prevailtherapeutics.com/
About Prevail Therapeutics
Prevail Therapeutics is a biotechnology company focused on developing novel biologic therapies for Parkinson’s Disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
YEAR FOUNDED:
2017
LEADERSHIP:
Founders: Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, OrbiMed, and Asa Abeliovich
32 articles about Prevail Therapeutics
-
Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations
6/4/2019
Prevail Therapeutics Inc., a gene therapy company developing AAV-based gene therapies for patients with neurodegenerative diseases, today announced the U.S. Food and Drug Administration has accepted the Company’s Investigational New Drug application for its lead gene therapy program, PR001.
-
BioSpace Movers and Shakers, May 17
5/17/2019
Biopharma companies add new leaders to executive roles and boards of directors. -
Prevail Therapeutics Announces Executive Team Promotion and Appointments to Board of Directors
5/16/2019
Yong Dai, Ph.D., Promoted to Chief Technology Officer Tim Adams Joins Board of Directors; Francois Nader, M.D., Role Expanded to Non-Executive Chairman
-
Prevail Therapeutics Secures $50 Million in Series B Financing to Advance Pipeline of Gene Therapies for Neurodegenerative Diseases
3/27/2019
Prevail Therapeutics Inc. (Prevail), a gene therapy company developing AAV-based gene therapies for patients with devastating neurodegenerative diseases, today announced it has raised $50 million in Series B financing
-
Prevail Therapeutics Announces Executive Leadership Appointments
12/5/2018
Brett Kaplan, M.D., Joins as Chief Financial Officer Emily Minkow Promoted to Chief Business Officer
-
Cardurion Pharmaceuticals Appoints Rebecca Frey as Chief Operating Officer
7/24/2018
Cardurion Pharmaceuticals, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D.
-
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
-
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
-
Prevail Therapeutics Appoints Industry Leader Francois Nader, M.D., to its Board of Directors
5/24/2018
Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced the appointment of Francois Nader, M.D., to its Board of Directors.
-
Seven months after Prevail Therapeutics launched, the company has secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease.
-
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson’s and Other Neurodegenerative Diseases
3/8/2018
Investors in the round included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners L.P., Boxer Capital, LLC, Adage Capital Management L.P., and Alexandria Venture Investments.
-
Drumroll... New Company Prevail Therapeutics Launched
8/10/2017